Formula Growth Ltd. Invests $1.95 Million in HCA Healthcare, Inc. $HCA

Formula Growth Ltd. purchased a new position in HCA Healthcare, Inc. (NYSE:HCAFree Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,000 shares of the company’s stock, valued at approximately $1,949,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sumitomo Life Insurance Co. lifted its position in HCA Healthcare by 1.0% during the 4th quarter. Sumitomo Life Insurance Co. now owns 2,026 shares of the company’s stock valued at $946,000 after acquiring an additional 20 shares during the period. MJP Associates Inc. ADV grew its holdings in HCA Healthcare by 2.9% in the fourth quarter. MJP Associates Inc. ADV now owns 749 shares of the company’s stock worth $350,000 after purchasing an additional 21 shares during the period. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of HCA Healthcare by 7.5% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 300 shares of the company’s stock valued at $140,000 after purchasing an additional 21 shares during the last quarter. Anchyra Partners LLC increased its position in HCA Healthcare by 3.7% during the 1st quarter. Anchyra Partners LLC now owns 587 shares of the company’s stock valued at $278,000 after buying an additional 21 shares in the last quarter. Finally, Plato Investment Management Ltd raised its stake in HCA Healthcare by 0.6% during the fourth quarter. Plato Investment Management Ltd now owns 3,908 shares of the company’s stock valued at $1,833,000 after buying an additional 22 shares during the last quarter. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Stock Performance

HCA Healthcare stock opened at $419.19 on Friday. The stock has a market cap of $90.75 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.48 and a beta of 1.10. The stock has a fifty day moving average of $400.24 and a 200 day moving average of $441.63. HCA Healthcare, Inc. has a one year low of $353.99 and a one year high of $556.52.

HCA Healthcare (NYSE:HCAGet Free Report) last released its quarterly earnings results on Friday, July 24th. The company reported $7.59 EPS for the quarter, beating the consensus estimate of $7.56 by $0.03. The firm had revenue of $20.23 billion during the quarter, compared to analyst estimates of $19.76 billion. HCA Healthcare had a net margin of 8.77% and a negative return on equity of 244.79%. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.84 EPS. As a group, sell-side analysts predict that HCA Healthcare, Inc. will post 29.42 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 16th will be paid a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is currently 10.45%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Oppenheimer reduced their price target on HCA Healthcare from $520.00 to $485.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Barclays reduced their price objective on shares of HCA Healthcare from $402.00 to $387.00 and set an “equal weight” rating for the company in a research note on Monday, July 27th. UBS Group dropped their target price on shares of HCA Healthcare from $635.00 to $579.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Truist Financial decreased their price objective on shares of HCA Healthcare from $535.00 to $495.00 and set a “buy” rating for the company in a report on Monday, July 27th. Finally, Morgan Stanley cut their target price on HCA Healthcare from $425.00 to $380.00 and set an “underweight” rating on the stock in a research note on Monday, July 27th. Fourteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $462.64.

Read Our Latest Stock Analysis on HCA Healthcare

HCA Healthcare Profile

(Free Report)

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.

Featured Stories

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCAFree Report).

Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.